logo
  Join        Login             Stock Quote

My Best Healthcare Stock Picks For 2013

 December 04, 2012 11:39 PM
 


Last year at this time, I made a screen of some stocks from the healthcare sector with an interesting market valuation, a great past growth performance as well as good earnings situation. The stocks had a forward P/E of less than 15, a sales growth over the recent five years of more than 10 percent as well as an operating margin over 10 percent. Exactly seven stocks fulfilled these criteria at that time. Today I like to review these picks and try to discover a new list of potential stocks for next year, 2013. 

Over the recent year the Dow Jones Index is up 8.36 percent, the S&P 500 gained 13.82 percent and the NASDAQ is 14.58 percent higher. My seven healthcare picks from last year performed in average 31.55 percent while the healthcare sector summarized a total gain of 25.7 percent. Below is a current screen of the seven picks with performance figures.

Performance Review Of The Healthcare Picks 2012 (Click to enlarge)

[Related -Celgene Corporation (NASDAQ:CELG): Why Should You Invest In Celgene In 2014?]

[Related -St. Jude Medical, Inc. (NYSE:STJ): A Stock With Potential To Outperform Peers]

The bad news for me is that I don't have invested in one of them. Now I try to make a similar screen with attractive price ratios. The only new restrictions are simple. I allow lower capitalized stocks (over USD 2 billion market capitalization) and introduce a new barrier in terms of earnings growth. I want mid-term (next five years) earnings per share growth of more than 5 percent. Thirteen companies remain.

Here are my favorite stocks:

Abbott Laboratories (NYSE:ABT) has a market capitalization of $102.74 billion. The company employs 91,000 people, generates revenue of $38.851 billion and has a net income of $4.728 billion. The firm's earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $8.795 billion. The EBITDA margin is 22.64 percent (the operating margin is 14.81 percent and the net profit margin 12.17 percent).

Financial Analysis: The total debt represents 25.57 percent of the company's assets and the total debt in relation to the equity amounts to 63.07 percent. Due to the financial situation, a return on equity of 20.07 percent was realized. Twelve trailing months earnings per share reached a value of $4.11. Last fiscal year, the company paid $1.92 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 15.81, the P/S ratio is 2.64 and the P/B ratio is finally 4.18. The dividend yield amounts to 3.14 percent and the beta ratio has a value of 0.32.

Long-Term Stock History Chart Of Abbott Laboratories (ABT)
Long-Term Dividends History of Abbott Laboratories (ABT)
Long-Term Dividend Yield History of Abbott Laboratories (ABT)

Herbalife (NYSE:HLF) has a market capitalization of $4.96 billion. The company employs 5,100 people, generates revenue of $3.454 billion and has a net income of $412.58 million. The firm's earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $634.12 million. The EBITDA margin is 18.36 percent (the operating margin is 16.28 percent and the net profit margin 11.94 percent).

Financial Analysis: The total debt represents 14.08 percent of the company's assets and the total debt in relation to the equity amounts to 36.35 percent. Due to the financial situation, a return on equity of 78.78 percent was realized. Twelve trailing months earnings per share reached a value of $3.88. Last fiscal year, the company paid $0.73 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 11.84, the P/S ratio is 1.44 and the P/B ratio is finally 9.50. The dividend yield amounts to 2.61 percent and the beta ratio has a value of 1.70.

Long-Term Stock History Chart Of Herbalife (HLF)
Long-Term Dividends History of Herbalife (HLF)
Long-Term Dividend Yield History of Herbalife (HLF)

Teva Pharmaceuticals (NYSE:TEVA) has a market capitalization of $35.02 billion. The company employs 45,754 people, generates revenue of $18.312 billion and has a net income of $2.829 billion. The firm's earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $4.174 billion. The EBITDA margin is 22.79 percent (the operating margin is 16.98 percent and the net profit margin 15.45 percent).

Financial Analysis: The total debt represents 28.95 percent of the company's assets and the total debt in relation to the equity amounts to 65.40 percent. Due to the financial situation, a return on equity of 12.50 percent was realized. Twelve trailing months earnings per share reached a value of $2.44. Last fiscal year, the company paid $0.95 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 16.52, the P/S ratio is 2.08 and the P/B ratio is finally 1.71. The dividend yield amounts to 2.55 percent and the beta ratio has a value of 0.36.

Long-Term Stock History Chart Of Teva Pharmaceuticals (TEVA)
Long-Term Dividends History of Teva Pharmaceuticals (TEVA)
Long-Term Dividend Yield History of Teva Pharmaceuticals (TEVA)

Take a closer look at the full list of next year's best healthcare stock picks. The average P/E ratio amounts to 19.60 and forward P/E ratio is 16.84. The dividend yield has a value of 2.75 percent. Price to book ratio is 3.46 and price to sales ratio 2.06. The operating margin amounts to 15.16 percent. The average stock has a debt to equity ratio of 0.92.

Here is the full table with some fundamentals (TTM):

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageGoogle Inc. (GOOGL) Q2 Earnings Preview: A Few Pennies Either Way Make a Big Difference.

Google Inc. (NASDAQ:GOOGL) will hold its quarterly conference call to discuss second quarter 2014 financial read on...

article image19 Companies That Could Beat Earnings and Pop on Price Next Week

Using iStock’s proprietary iEstimates model, we have identified 19 publicly traded companies that could read on...

article imageIntel Corporation (INTC): Analysts believe PC Replacement Cycle Will Stretch Valuation Metrics

Intel Corporation (NASDAQ:INTC) rocked on Humpday thanks to better than expected earnings, forward guidance read on...

article imageSanDisk Corporation (SNDK) Q2 Earnings Preview: Beat and Pop

SanDisk Corporation (NASDAQ:SNDK) will host a conference call Wednesday, Jul. 16, 2014 at 2 p.m., Pacific, read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.